Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism

Journal of Endocrinological Investigation

Volumn 33, Issue 4, 2010, Pages 228-233

  Lueblinghoff, J ^a   Mueller, S ^a   Sontheimer, J ^a   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Gain of function mutation; Linear regression analysis; Non autoimmune hyperthyroidism; Sporadic germline mutation; TSH receptor mutation

Indexed keywords

HORMONE RECEPTOR; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FOLLOW UP; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTHYROIDISM; IN VITRO STUDY; MUTATIONAL ANALYSIS; SYSTEMATIC REVIEW; FETUS; GENETIC ASSOCIATION; GENETICS; INFANT; MUTATION; ONSET AGE; PHYSIOLOGY; STATISTICAL MODEL;

AGE OF ONSET; FETUS; GENETIC ASSOCIATION STUDIES; HUMANS; HYPERTHYROIDISM; INFANT; LINEAR MODELS; MUTATION; RECEPTORS, THYROTROPIN;

EID: 77953555138     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6476     Document Type: Article

References (42)

1. Gruters A, Schöneberg T, Biebermann H, et al. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J Clin Endocrinol Metab 1998, 83: 1431-6.
2. Chester J, Rotenstein D, Ringkananont U, et al. Congenital neonatal hyperthyroidism caused by germline mutations in the TSH receptor gene. J Pediatr Endocrinol Metab 2008, 21: 479-86.
3. Borgel K, Pohlenz J, Koch HG, Bramswig JH. Long-term Carbimazole treatment of neonatal nonautoimmune hyperthyroidism due to a new activating TSH receptor gene mutation (Ala428Val). Horm Res 2005, 64: 203-8.
4. de Roux N, Polak M, Couet J, et al. A neomutation of the thyroidstimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab 1996, 81: 2023-6.
5. Lavard L, Sehested A, Brock Jacobsen B, et al. Long-term follow-Up of an infant with thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr). Horm Res 1999, 51: 43-6.
6. Holzapfel HP, Wonerow P, von Petrykowski W, Henschen M, Scherbaum WA, Paschke R. Sporadic congenital hyperthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene. J Clin Endocrinol Metab 1997, 82: 3879-84.
7. Führer D, Mix M, Wonerow P, Richter I, Willgerodt H, Paschke R. Variable phenotype associated with Ser505Asn-activating thyrotropin-receptor germline mutation. Thyroid 1999, 9: 757-61.
8. Nishihara E, Fukata S, Hishinuma A, et al. Sporadic congenital hyperthyroidism due to a germline mutation in the thyrotropin receptor gene (Leu 512 Gln) in a Japanese patient. Endocr J 2006, 53: 735-40.
9. Tonacchera M, Agretti P, Rosellini V, et al. Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene. Thyroid 2000, 10: 859-63.
10. Watkins MG, Dejkhamron P, Huo J, Vazquez DM, Menon RK. Persistent neonatal thyrotoxicosis in a neonate secondary to a rare thyroid-stimulating hormone receptor activating mutation: case report and literature review. Endocr Pract 2008, 14: 479-83.
11. Esapa CT, Duprez L, Ludgate M, et al. A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis. Thyroid 1999, 9: 1005-10.
12. Kopp P, van Sande J, Parma J, et al. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995, 332: 150-4.
13. Kopp P, Jameson JL, Roe TF. Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by a sporadic germline mutation in the thyrotropin receptor gene. Thyroid 1997, 7: 765-70.
14. Bircan R, Miehle K, Mladenova G, et al. Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism. Exp Clin Endocrinol Diabetes 2008, 116: 341-6.
15. Duprez L, Parma J, Costagliola S, et al. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett 1997, 409: 469-74.
16. Ho SC, Van Sande J, Lefort A, Vassart G, Costagliola S. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity. Endocrinology 2001, 142: 2760-7.
17. Gozu HI, Bircan R, Krohn K, et al. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol 2006, 155: 535-54.
18. Wonerow P, Chey S, Führer D, Holzapfel HP, Paschke R. Functional characterization of five constitutively activating thyrotrophin receptor mutations. Clin Endocrinol (Oxf) 2000, 53: 461-8.
19. Trulzsch B, Krohn K, Wonerow P, et al. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 2001, 78: 684-91.
20. Parma J, Duprez L, Van SJ, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997, 82: 2695-701.
21. Claeysen S, Govaerts C, Lefort A, et al. A conserved Asn in TM7 of the thyrotropin receptor is a common requirement for activation by both mutations and its natural agonist. FEBS Lett 2002, 517: 195-200. (Pubitemid 34327658)
22. Mueller S, Gozu H, Bircan R, et al. Cases of borderline in vitro constitutive TSHR activity - how to decide whether a TSHR mutation is constitutively active or not? Thyroid 2009, 19: 765-73.
23. Jaeschke H, Kleinau G, Sontheimer J, Mueller S, Krause G, Paschke R. Preferences of transmembrane helices for cooperative amplification of G(alpha)s and G (alpha)q signaling of the thyrotropin receptor. Cell Mol Life Sci 2008, 65: 4028-38.
24. Meng W, Scriba PC. Jodversorgung in Deutschland. Probleme und erforderliche Maßnahmen: Update 2002. Dt Ärtzeblatt 2002, 99: A-2650.
25. Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab 1998, 83: 3401-8.
26. Delange FM. Control of Iodine Deficiency in Western and Central Europe. Cent Eur J publ Health 2003, 11: 120-3.
27. Hetzel BS, Delange F, Dunn JT, Ling J, Mannar V, Pandav CS eds. Towards the Global Elimination of Brain Damage due to Iodine Deficiency. New Delhi: OUP 2004.
28. Bürgi H, Portmann L, Podoba J, Vertongen F, Srbecky M. Thyroid volumes and urinary iodine in Swiss school children, 17 years after improved prophylaxis of iodine deficiency. Eur J Endocrinol 1999, 140: 104-6.
29. Delange F. Iodine deficiency in Europe and its consequences: an update. Eur J Nucl Med Mol Imaging 2002, 29: 404-16.
30. Vlaeminck-Guillem V, Ho SC, Rodien P, Vassart G, Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 2002, 16: 736-46.
31. Jaeschke H, Neumann S, Kleinau G, et al. An aromatic environment in the vicinity of serine 281 is a structural requirement for thyrotropin receptor function. Endocrinology 2006, 147: 1753-60.
32. Kleinau G, Jaeschke H, Mueller S, et al. Evidence for cooperative signal triggering at the extracellular loops of the TSH receptor. FASEB J 2008, 22: 2798-808.
33. Hjorth SA, Orskov C, Schwartz TW. Constitutive activity of glucagon receptor mutants. Mol Endocrinol 1998, 12: 78-86. (Pubitemid 28124781)
34. Ballesteros JA, Jensen AD, Liapakis G, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001, 276: 29171-7.
35. Srinivasan S, Lubrano-Berthelier C, Govaerts C, et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 2004, 114: 1158-64.
36. Akcurin S, Turkkahraman D, Tysoe C, et al. A family with a novel TSH receptor activating germline mutation (p.Ala485Val). Eur J Pediatr 2008, 67: 1231-7.
37. Liu Z, Sun Y, Dong Q, He M, Cheng CH, Fan F. A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism. J Hum Genet 2008, 53: 475-8.
38. Ferrara AM, Capalbo D, Rossi G, et al. A New Case of Familial Nonautoimmune Hyperthyroidism Caused by the M463V Mutation in the TSH Receptor with Anticipation of the Disease Across Generations: A Possible Role of Iodine Supplementation. Thyroid 2007, 17: 677-80.
39. Nwosu BU, Gourgiotis L, Gershengorn MC, Neumann S. A novel activating mutation in transmembrane helix 6 of the thyrotropin receptor as cause of hereditary nonautoimmune hyperthyroidism. Thyroid 2006, 16: 505-12.
40. Kopp P. The TSH receptor and its role in thyroid disease. Cell Mol Life Sci 2001, 58: 1301-22.
41. Duprez L, Parma J, Van SJ, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994, 7: 396-401. (Pubitemid 24204416)
42. Arturi F, Chiefari E, Tumino S, et al. Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation. J Endocrinol Invest 2002, 25: 696-701.